547 patients with SLE with anti-double stranded DNA or antinuclear antibodies and Safety of Estrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index ( SELENA-SLEDAI ) score 6 at baseline were randomised to receive placebo or blisibimod at one of 3 dose levels .